Objective: To evaluate the accuracy and influencing factors of T-stage restaging of rectal cancer following neoadjuvant therapy with endorectal ultrasonography (ERUS). Methods: In a retrospective study, endorectal ultrasound was performed in 86 patients with rectal cancer following neoadjuvant therapy. The imaging results were compared with postoperative pathological T-stage. Results: The accuracy of overall T-stage restaging with ERUS was 67.4% (58/86). Additionally, the accuracy of restaging in middle and high rectal cancer was higher, with an accuracy of 76.1%(35/46)and 100%(4/4) respectively. Univariate analysis showed that the location of tumors was an independent factor affecting the accuracy of ERUS(P=0.033). Conclusion: ERUS is an effective method to restage T-stage of rectal cancer following neoadjuvant therapy.
目的： 评价直肠腔内超声（ERUS）对直肠癌新辅助治疗后T再分期诊断的准确性以及影响准确性的因素。 方法： 回顾性分析2014年7月至2018年2月福建省肿瘤医院86例行新辅助放化疗后的直肠癌患者，术前通过ERUS检查并与术后病理T分期进行对照分析。 结果： ERUS的T再分期总体准确率为67.4%（58/86），中位和高位直肠癌的准确率较高分别为76.1%（35/46），100%（4/4）。单因素分析显示，肿瘤发生部位是影响ERUS准确性的独立因素（P值为0.033）。 结论： ERUS可作为直肠癌新辅助治疗后T再分期的有效手段。.
Keywords: Endosonography; Neoadjuvant therapy; Rectal neoplasms.